| A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse WKA Yung, RE Albright, J Olson, R Fredericks, K Fink, MD Prados, ... British journal of cancer 83 (5), 588-593, 2000 | 1207 | 2000 |
| Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial JE Karp, JE Lancet, SH Kaufmann, DW End, JJ Wright, K Bol, I Horak, ... Blood, The Journal of the American Society of Hematology 97 (11), 3361-3369, 2001 | 603 | 2001 |
| Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. A Thibault, D Samid, AC Tompkins, WD Figg, MR Cooper, RJ Hohl, ... Clinical cancer research: an official journal of the American Association …, 1996 | 480 | 1996 |
| Isoprenoids: remarkable diversity of form and function SA Holstein, RJ Hohl Lipids 39 (4), 293-309, 2004 | 286 | 2004 |
| Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 AA Miller, DJ Murry, K Owzar, DR Hollis, EB Kennedy, G Abou-Alfa, ... Journal of Clinical Oncology 27 (11), 1800, 2009 | 220 | 2009 |
| Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565 AP Venook, MJ Egorin, GL Rosner, D Hollis, S Mani, M Hawkins, J Byrd, ... Journal of clinical oncology 18 (14), 2780-2787, 2000 | 214 | 2000 |
| Anti-cancer therapy: targeting the mevalonate pathway KM Swanson, RJ Hohl Current cancer drug targets 6 (1), 15-37, 2006 | 206 | 2006 |
| Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation CK Lee, RD Gingrich, RJ Hohl, KA Ajram Bone marrow transplantation 16 (1), 175-182, 1995 | 187 | 1995 |
| Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent J Kang, V Kumar, D Yang, PR Chowdhury, RJ Hohl European journal of pharmaceutical sciences 15 (2), 163-170, 2002 | 184 | 2002 |
| Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma A Gronchi, BN Bui, S Bonvalot, S Pilotti, S Ferrari, P Hohenberger, ... Annals of oncology 23 (3), 771-776, 2012 | 169 | 2012 |
| Phase II study of high‐dose fish oil capsules for patients with cancer‐related cachexia: A Cancer and Leukemia Group B study CP Burns, S Halabi, G Clamon, E Kaplan, RJ Hohl, JN Atkins, ... Cancer 101 (2), 370-378, 2004 | 145 | 2004 |
| Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473 CP Burns, S Halabi, GH Clamon, V Hars, BA Wagner, RJ Hohl, E Lester, ... Clinical Cancer Research 5 (12), 3942-3947, 1999 | 145 | 1999 |
| Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. AP Venook, MJ Egorin, GL Rosner, TD Brown, TM Jahan, G Batist, R Hohl, ... Journal of clinical oncology 16 (5), 1811-1819, 1998 | 142 | 1998 |
| Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase SA Holstein, DM Cermak, DF Wiemer, K Lewis, RJ Hohl Bioorganic & medicinal chemistry 6 (6), 687-694, 1998 | 135 | 1998 |
| Differential effects of monoterpenes and lovastatin on RAS processing RJ Hohl, K Lewis Journal of Biological Chemistry 270 (29), 17508-17512, 1995 | 131 | 1995 |
| VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML L Wang, B Jia, DF Claxton, WC Ehmann, WB Rybka, S Mineishi, S Naik, ... Oncoimmunology 7 (9), e1469594, 2018 | 124 | 2018 |
| Consequences of mevalonate depletion: differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB SA Holstein, CL Wohlford-Lenane, RJ Hohl Journal of Biological Chemistry 277 (12), 10678-10682, 2002 | 112 | 2002 |
| Synergistic interaction of lovastatin and paclitaxel in human cancer cells SA Holstein, RJ Hohl Molecular cancer therapeutics 1 (2), 141-149, 2001 | 105 | 2001 |
| Synthesis and biological activity of isoprenoid bisphosphonates LW Shull, AJ Wiemer, RJ Hohl, DF Wiemer Bioorganic & medicinal chemistry 14 (12), 4130-4136, 2006 | 104 | 2006 |
| A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients E Messing, JR Gee, DR Saltzstein, KM Kim, A diSant'Agnese, J Kolesar, ... Cancer prevention research 5 (4), 621-630, 2012 | 102 | 2012 |
